Lab Owl™ Helps Outlook Therapeutics’ Grow with Flexible, Value-Driven Bioreactor Control and Information System
A Modular, Flexible and User-Friendly Lab Automation Approach Empowers Development Lab Success
Oncobiologics, Inc. (ONS), now known as Outlook Therapeutics, Inc. was founded in 2010 and started operations in 2011. By 2012, the organization began setting up their first lab to develop approximately six early-stage biosimilars.
ONS understood that they needed robust upstream and downstream processes. The organization also knew they needed a highly flexible bioreactor control and information system, but as a startup organization that had just begun R&D, budget was a challenge.
ONS began their search for a new lab automation and control partner. Former Bristol-Myers Squibb (BMS) staff who joined ONS at the time recommended Lab Owl and they two companies began their collaboration. Lab Owl was tasked with customizing its bioreactor and information control system to meet ONS’ unique development lab needs while remaining within the company’s limited start-up budget.
What ONS is Saying...
Two Lab Owl Features
That Made ONS Scientist’s Jobs Easier…
The bioreactor control system implemented for ONS provided robust controls and features at about half the price when compared to larger, more traditional suppliers. Lab Owl’s modular, open system architecture also allowed ONS to cut costs by purchasing third party lab components that could be integrated and used within Lab Owl’s lab automation and control system.
The tunable, incredibly user-friendly, intuitive system empowered the ONS team to dictate and control its processes while minimizing human error.